Ratings Evogene Ltd.

Equities

EVGN

IL0011050551

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:13 2024-05-16 am EDT 5-day change 1st Jan Change
249.1 ILa -3.86% Intraday chart for Evogene Ltd. -6.35% -16.91%

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-16.91% 34.13M - -
+33.63% 50.85B
B-
-0.09% 42.82B
B
+49.62% 42.03B
A
-4.96% 29.55B
C
+11.18% 26.11B
B-
-21.95% 19.13B
B
+8.61% 13.05B
B+
+28.31% 12.16B
C+
+24.73% 12.08B
B+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW